Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray
Go back to Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 28.02 +0.16 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.86 | 52 Week High | $42.49 | |||
| Open | $27.77 | 52 Week Low | $16.64 | |||
| Day High | $28.19 | P/E | N/A | |||
| Day Low | $27.65 | EPS | $-0.42 | |||
| Volume | 1,682,951 | |||||
